IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 3100 participants.

Also called NCT04221815

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 3,100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04221815
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Cyprus, Germany, Greece, Israel, Italy, Sweden, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04221815. Randomized; single masking; primary purpose treatment. Start 2020-10-14 (actual); primary completion 2026-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact
Acronym
IMPROVE
Condition
Atherosclerosis
Intervention (Device)
Eagle Eye Platinum digital IVUS catheter with optional SyncVision
Intervention (Device)
Resolute Onyx Drug Eluting Stent
Intervention (Device)
Onyx Frontier Drug Eluting Stent
Intervention (Device)
Onyx TruStar Drug Eluting Stent
Intervention (Device)
Onyx TruCor Drug Eluting Stent
Lead sponsor
Medstar Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct04221815
Content hash
8bf6593c6fdad0f3130a7b790bb15154865df9a6c9521e0325ddd95d207f3789